Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145245 | 0.86 | PDE4A (0.50) | FGFR1YTHDC1XDHKEAP1NFE2L2 | |
| SCHEMBL3138702 | 0.84 | XDH (0.50) | TLR7YTHDC1XDH | |
| SCHEMBL3145902 | 0.83 | YTHDC1 (0.55) | YTHDC1MET | |
| SCHEMBL3137312 | 0.83 | TLR7 (0.42) | FGFR1TLR7YTHDC1XDHCSNK1D | |
| SCHEMBL3146372 | 0.83 | XDH (0.42) | TLR7YTHDC1XDHCSNK1DCSNK1E | |
| SCHEMBL3140675 | 0.83 | TLR7 (0.53) | TLR7YTHDC1XDH | |
| SCHEMBL3137223 | 0.82 | YTHDC1 (0.54) | TLR7YTHDC1XDH | |
| SCHEMBL3146233 | 0.82 | XDH (0.46) | FGFR1TLR7YTHDC1XDHALDH1A1 | |
| SCHEMBL3142327 | 0.82 | PIM1 (0.44) | TLR7YTHDC1 | |
| SCHEMBL3141022 | 0.81 | NR1H2 (0.46) | TLR7YTHDC1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2010-01-14 | — | — | US | claimed |
| CN-100439370-C | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-12-03 | — | — | CN | claimed |
| US-20080119495-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2008-05-22 | — | — | US | claimed |
| US-7342021-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-03-11 | — | — | US | claimed |
| US-7332486-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-02-19 | — | — | US | claimed |
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-26 | — | — | US | claimed |
| CN-1688580-A | 2-Trifluoromethyl-6-aminopurine derivatives as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | claimed |
| EP-1529049-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-05-11 | — | — | EP | claimed |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | LIU RUIPING (US) | 2004-12-02 | — | — | US | claimed |
| CN-1501927-A | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | 记忆药物公司 | 2004-06-02 | — | — | CN | claimed |
| WO-2004014913-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | claimed |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-03-06 | — | — | US | claimed |
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2010-01-14 | — | — | US | disclosed |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2010-01-07 | — | — | US | disclosed |
| EP-1529049-B1 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| CN-100439370-C | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-12-03 | — | — | CN | disclosed |
| CN-1501927-A | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | 记忆药物公司 | 2004-06-02 | — | — | CN | disclosed |
| EP-1383767-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-03-06 | — | — | US | disclosed |
| WO-2002098878-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE3A | FGFR1 1656/4885ABCG2 2133/4885TLR7 4771/4885 |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | FGFR1 2005/4885ABCG2 2382/4885TLR7 4751/4885 |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | FGFR1 1656/4885ABCG2 2133/4885TLR7 4771/4885 |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | FGFR1 2005/4885ABCG2 2382/4885TLR7 4751/4885 |
| US-20080119495-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | FGFR1 1656/4885ABCG2 2133/4885TLR7 4771/4885 |
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | FGFR1 1656/4885ABCG2 2133/4885TLR7 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.